Discussion  by unknown
Acquired Cardiovascular Disease Stulak et al
A
C
Densure transmural atrial lesions and, thus, maximized the
potential for ablation of AF. Furthermore, as observed in
the present series, the Cox maze III procedure offers
significantly greater freedom from AF compared with
alternate energy sources and lesion sets. Patient factors,
including risks and benefits, should always be considered
when planning AF ablation to optimize the lesion set and
energy source applied. Although wemight consider isolated
PVI to potentially be adequate for a patient with paroxysmal
AF, a more complete BA lesion set might be required for
patients with more long-standing AF and complex
valvular disease, in whom the pathogenesis of AF could
be completely different. It is not clear whether newer
procedures have definitively demonstrated equivalency to
the Cox maze III procedure with limited series and
follow-up data. Although these technologies and alternate
approaches can be appropriate in select patients, the Cox
maze III procedure remains the reference standard for the
surgical treatment of AF and should still be considered,
especially for patients for whom AF ablation is of critical
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Dr Ralph J. Damiano, Jr (St Louis, Mo). Dr Stulak, thank you
for providing me with the report and congratulations on a superb
presentation.
This is a very interesting study, and I think it illustrates one of
the problems with looking back at a long retrospective experience
from either a single or multiple centers. One of the greatest
problems with your data is that the groups were extremely
heterogeneous, just as you have alluded, and it is almost
impossible to account for all those variables when you examine
your data.
Perhaps the most single important variable is the surgeon
experience and technical proficiency with the different procedures.
My first question for you is whether you controlled for the surgeon
performing the ablation procedures? I know historically at least at
your institution, Dr Schaff has been a real proponent of the cut and
sew procedure. If he performed all the cut and sew operations and
other surgeons with varying levels of experience performed the
other ablation procedures, how did you take that into account?
Dr Stulak. That is a great point. We did not control for the
surgeon. Just as I stated in the last line, I do not know how
generalizable our data will be, because this was basically our
experience. Actually 4 surgeons throughout the study period
performed the CSM, with the 90-whatever percent performed by
Dr Schaff; thus, this was almost a comparison of what he
does during his mitral valve operations compared with 8 to
12 other surgeons during that same period using alternate energy
sources. So, you were exactly right, it would be difficult to control
for that.
But this is not the end game for us. This is just the beginning,
studying how we can better evaluate new technology and control
for confounders at the same time. I think I have learned a lot
and will continue to do so.
Dr Damiano. No, I think that is a really important point. You
really cannot underestimate that variable.
I will just share an anecdote from one of the large multicenter
trials in which we recruited a number of centers, all with very
experienced surgeons who all were trained to perform the Cox
maze IV procedure. The center-to-center variability in the success
rate, as adjudicated by an independent core laboratory, ranged
from 0% to 100%. You might say that this is either the greatest
procedure ever invented or the worst. But it really is related to
how it was performed. The take home message from your study
should not be that one should always perform a Cox maze III
procedure. Because it is interesting, even at your own institution,gery c May 2014
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Dr Stulak. No, absolutely. I think the message from our
report is, is that results are different. Also, although we have this
new technology, we should not become complacent and say,
‘‘Wow, we have this great technology.’’ We can compare it with
an operation we know has yielded wonderful results and for us
to continue to evolve and always improve that technology. We
are certainly not saying ‘‘let us go back in time,’’ necessarily
because of the reasons it was abandoned in the first place probably.
However, I think there still is a niche for it, and I think it does serve,
we have the most data for it; thus, I think it will serve as a
comparator group as we move toward new technologies and
approaches.
DrDamiano.Yes, I think that is an excellent point, that it serves
as a great reference standard.
My last question and comment on your data is that, although
admittedly the guidelines were not published until 2007,
when we present reports on the surgical ablation of AF it is
not adequate just to present electrocardiograph follow-up data.
We know that that really underestimates the rate. Do you have a
subset of patients that met the minimum criteria for follow-up,
which would be a 24-hour Holter or pacemaker interrogation,The Journal of Thoracic and Carand have you studied your results when you have adequate
follow-up data?
Dr Stulak. This is a great point. Unfortunately, we did not
have Holter monitoring data for the comparator group, and we
believe that using 2 different methods of rhythm evaluation
would not have been appropriate. We have begun to follow
patients with Holter monitoring during follow-up in the current
era. However, if you use the same monitoring method for all
patients, you would like to assume that it would overestimate the
success for all patients. Thus,wewanted to at least not compareHol-
ter versus old-time ECGs. So, you are right, although that was one
caveat that I throw myself on the sword for in the presentation, we
had to have similar comparator groups, at least for this analysis.
Dr Damiano. A final quick question. Many of the large studies
have shown for both catheter and surgical ablation that LA size is a
predictor of failure. I notice that did not come out in your
multivariate analysis. Is that because you did not have enough
data, particularly from the older part of your series, or was that
really not a predictor of failure?
Dr Stulak. No, in our earlier report we saw a 55-mm cutoff.
This did not come out. I would suggest that we did not have
adequate echocardiographic data beforehand, either, in patients
undergoing coronary artery bypass grafting.diovascular Surgery c Volume 147, Number 5 1487
